GLP-1 series
Module 10 · Myths
GLP-1 Receptor Agonists: Myths, Misconceptions & Media Headlines
What a GLP-1 actually is, four brands and two molecules, the myths worth retiring, and the difference between an exciting signal and an oversold headline.
11 slides · 12 minutes
Video coming soon
12-minute recorded module
What this module covers
- 01A quiet drug boom reshaping risk
- 02What a GLP-1 actually is
- 03Four brands, two molecules, two makers
- 04Myth versus evidence, twice over
- 05Signal versus noise in the headlines
- 06The cost and coverage reality
- 07Reading the label: the real safety profile
Key takeaways
The brand name signals the approved use, not a different drug.
Some findings are genuinely exciting; others are oversold.
Sourcing matters as much as the molecule.
Continue the series
Module 1
GLP-1–Based Therapies in Cardio-Oncology
Module 2
GLP-1 Receptor Agonist Therapy: The Complete Briefing
Module 3
Obesity, Cardiometabolic Health & GLP-1 Therapies
Educational information only. It does not replace advice from your oncology or primary care team, and no treatment decision should be made from this module alone.